FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHA	NGES IN E	BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	rden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Monia Brett P					2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ISIS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Wolld Diett P														X Directo	r		10% Ow	/ner		
	⁻ ├─								_		(give title		Other (s	pecify						
(Last)	(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)							below)	below)		below)			
C/O ISIS PHARMACEUTICALS, INC.				101	01/01/2012								5	Senior Vice President						
2855 GA	ZELLE CO	HIRT																		
2000 GILLELL GOORI						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)					- - -		ciiuiiieiii,	Date	Ji Origiriai	ı ileu	(WOTH / Day	y/ icai)	Lin		oii il Gioup	ı ııııg	(Clieck App	ilicable		
CARLSI	BAD C.	Δ	92010											X Form f	led by One	Repo	rting Persor	1		
CARLSI	JAD C.	Α	32010											Form f	led by More	e than	One Repor	tina		
					-									Persor						
(City)	(S	itate)	(Zip)																	
		Tal	ble I - Nor	n-Deriv	vativ	re Se	curitie	s Ac	auired.	Dis	posed o	f. or Be	neficia	ly Owned						
4 Tiple - 6	2			2. Trans					-		1	-				6 00	manahin .	7. Nature of		
1. Title of Security (Instr. 3) 2. Trans			Date		ection 2A. Deemed Execution Date,			3. 4. Securities Acquired (A) of Transaction Disposed Of (D) (Instr. 3, 4								ndirect				
(Mo				(Month/I	n/Day/Year)		if any (Month/Day/Year)		Code (Instr. ar) 8)							Beneficial Ownership				
						(Worth Day Tear)		′ "			1	_	Reporte	d		(1113411 4)	(Instr. 4)			
										٧	Amount	(A) or (D)	Price		Fransaction(s) Instr. 3 and 4)					
					4 (0.04	/2012			(1)			 ` _	AC 15	- ` -	,					
Common Stock 01/01				1/201	/2012 01/01/2012		J ⁽¹⁾	V	587 D		\$6.12	85 5,	5,660		D					
			Table II -	Deriva	ative	Sec	urities	Aca	uired. D	isp	osed of.	or Bene	eficially	/ Owned						
											onvertik			,						
1. Title of	2.	3. Transaction	3A. Deemed	1 4	4.		5. Numb	oer	6. Date Ex	ercisa	able and	7. Title an	d Amoun	8. Price of	9. Numbe	r of	10.	11. Nature		
Derivative	Conversion Date Execution Date				Code (Instr.				Expiration Date of Securities (Month/Day/Year) Underlying Derivative Sec			ies	Derivative	derivative	.	Ownership	of Indirect			
Security or Exercise (Month/Day/Year) if any (Instr. 3) Price of (Month/Day/Year)													Security (Instr. 5)	Securities Beneficially Owned		Form: Direct (D) or Indirect	Beneficial Ownership			
Derivative					-,	Acquir				(Instr. 3 and 4)							((Instr. 4)		
Security						(A) or Disposed of (D) (Instr. 3, 4 and 5)							Following Reported	'	(I) (Instr. 4)					
														Transactio						
				⊢			3, 4 and	9,					T .	4	(111311. 4)					
								H					Amount							
													Number	•						
				(Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	of Shares							
Employee				\dashv				Н		\dashv			\vdash			-				
Stock								H				Common	l							
Option	\$7.21	01/01/2012	01/01/20	12	A		7,500	H	01/01/2013	3 ⁽²⁾	12/31/2021	Stock	7,500	\$0	7,500		D			
(right to buy)																				
Employee		 		\dashv				H		\dashv				1				1		
Stock		I										Common								
Option	\$7.25	01/03/2012	01/03/20	12	Α		18,993		01/03/2013	3 ⁽³⁾	01/02/2022	Stock	18,993	\$0	18,993	3	D			
(right to		1						ıl						1				1		

Explanation of Responses:

- 1. Reporting 587 shares acquired under the Isis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2012. Theses 587 shares may not be sold until July 2, 2012.
- 2. Grant of 1/1/12 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/1/13. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 1,875 shares per year. The option is exercisable as to 0 shares on 1/1/12.
- 3. Grant of 1/3/12 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/3/13. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 4,749 shares per year. The option is exercisable as to 0 shares on 1/3/12.

Remarks:

/s/B. Lynne Parshall, Attorney-In-Fact

01/03/2012

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.